Viracta Therapeutics Company Description
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide.
Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.
The company’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.
Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate.
The company is headquartered in Cardiff, California.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Craig Jalbert |
Contact Details
Address: 2533 South Coast Highway 101 Cardiff, Delaware 92007 United States | |
| Phone | 858 400 8470 |
| Website | viracta.com |
Stock Details
| Ticker Symbol | VIRX |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US92765F1084 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Craig R. Jalbert CIRA | Chief Executive Officer, President, Chief Financial Officer, Treasurer, Corporate Secretary and Director |